The GSK3β inhibitors TFGF-18 and ISO modulate the gut homeostasis and barrier function to inhibit neuroinflammation and attenuate cognitive impairment by regulating NF-κB, and Nrf2/HO-1 pathways. The gene discussed is GSK3B; the disease is Cognitive impairment.